bioRxivPharmacology & ToxicologyPreprint
Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2
Y. I. Anglero-Rodriguez, F. A. Lempp, J. McIninch, M. K. Schlegel, C. R. Brown, D. J. Foster, A. B. Castoreno, T. Nguyen, M. Subramanian, M. Montiel-Ruiz, H. Kaiser, A. Sahakyan, R. Spreafico, S. S. Morskaya, J. D. Barry, D. Berman, S. Lefebvre, A. Kasper, T. Racie, D. Weddle, M. Mobley, A. Rogers, J. Dybowski, S. Chong, J. Nair, , V. Jadhav
Abstract
RNA interference is a natural antiviral mechanism that could be harnessed to combat SARS-CoV-2 infection by targeting and destroying the viral genome. We screened lipophilic small-interfering RNA (siRNA) conjugates targeting highly conserved regions of the SARS-CoV-2 genome and identified leads targeting outside of the spike-encoding region capable of achieving [≥]3-log viral reduction. Serial passaging studies demonstrated that a two-siRNA combination prevented development of resistance compared to a single-siRNA approach. A two-siRNA combination delivered intranasally protected Syrian hamsters from weight loss and lung pathology by viral infection upon prophylactic administration but not following onset of infection. Together, the data support potential utility of RNAi as a prophylactic approach to limit SARS-CoV-2 infection that may help combat emergent variants, complement existing interventions, or protect populations where vaccines are less effective. Most importantly, this strategy has implications for developing medicines that may be valuable in protecting against future coronavirus pandemics.
- organism: mouse
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genome wide screen of RNAi molecules against SARS-CoV-2 creates a broadly potent prophylaxis
Ohad Yogev, Omer Weissbrod, … Yaniv Erlich·bioRxiv·Apr 12, 2022
- RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection
S. Marx, B. M. Kuemmerer, … G. Hartmann·bioRxiv·Aug 6, 2021
- Prophylactic intranasal administration of a TLR2 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model
P. C. Proud, D. Tsitoura, … M. W. Carroll·bioRxiv·Sep 25, 2020
- A stem-loop RNA RIG-I agonist confers prophylactic and therapeutic protection against acute and chronic SARS-CoV-2 infection in mice
T. Mao, B. Israelow, … A. Iwasaki·bioRxiv·Jun 16, 2021
- Intranasal delivery of lipid nanoparticle encapsulated SARS-CoV-2 and RSV-targeting siRNAs reduces lung infection
A. Supramaniam, Y. Tayyar, … A. Idris·bioRxiv·Jul 25, 2022
- A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19
Adi Idris, Alicia M. Davis, … Kevin V. Morris·Molecular TherapyPeer-reviewed·May 13, 2021